FABBRI, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 3.749
EU - Europa 2.848
AS - Asia 726
AF - Africa 139
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 7.481
Nazione #
US - Stati Uniti d'America 3.741
GB - Regno Unito 693
DE - Germania 517
SE - Svezia 493
IT - Italia 412
CN - Cina 263
IE - Irlanda 193
VN - Vietnam 191
IN - India 190
FR - Francia 150
RU - Federazione Russa 78
AT - Austria 77
ZA - Sudafrica 60
EE - Estonia 48
TG - Togo 47
JO - Giordania 44
UA - Ucraina 38
BG - Bulgaria 30
CH - Svizzera 28
BE - Belgio 26
CI - Costa d'Avorio 26
PL - Polonia 13
NL - Olanda 10
SG - Singapore 10
CZ - Repubblica Ceca 9
BR - Brasile 7
EU - Europa 7
IL - Israele 7
CA - Canada 6
GR - Grecia 6
LB - Libano 6
UZ - Uzbekistan 6
FI - Finlandia 5
LT - Lituania 3
NO - Norvegia 3
PK - Pakistan 3
SC - Seychelles 3
AU - Australia 2
ES - Italia 2
HK - Hong Kong 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
NG - Nigeria 2
PT - Portogallo 2
RO - Romania 2
SI - Slovenia 2
BA - Bosnia-Erzegovina 1
CL - Cile 1
DK - Danimarca 1
FK - Isole Falkland (Malvinas) 1
JP - Giappone 1
MA - Marocco 1
MK - Macedonia 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
Totale 7.481
Città #
Fairfield 667
Southend 633
Ashburn 400
Woodbridge 286
Seattle 283
Wilmington 248
Chandler 243
Houston 228
Princeton 214
Cambridge 207
Dublin 192
Ann Arbor 178
Bologna 109
Dong Ket 104
Frankfurt am Main 88
Westminster 62
Vienna 60
San Diego 57
Padova 52
Nanjing 51
Lomé 47
Berlin 46
Amman 44
Shenyang 33
Turin 33
Saint Petersburg 30
Sofia 29
Abidjan 26
Jinan 26
Olalla 25
Bern 22
Hebei 22
Mülheim 22
Milan 20
Nanchang 18
Des Moines 16
Boardman 15
Brussels 14
Paris 14
Tianjin 13
Changsha 12
Jacksonville 12
London 12
Redmond 12
Rome 12
Antwerpen 11
Chicago 11
Falls Church 11
Jiaxing 11
Redwood City 9
Beijing 8
Faenza 8
Haikou 8
Hangzhou 8
Medford 8
Norwalk 8
Dearborn 7
Los Angeles 7
Warsaw 7
Washington 7
Bolzano 6
Cesena 6
Lambeth 6
Lanzhou 6
Leawood 6
Occhiobello 6
Ravenna 6
Guangzhou 5
Shanghai 5
Hounslow 4
Montefiore Conca 4
New York 4
São Paulo 4
Brescia 3
Costa Mesa 3
Florence 3
Fuzhou 3
Grafing 3
Hefei 3
Herzliya 3
Lappeenranta 3
Modena 3
Ningbo 3
Oslo 3
Ostrava 3
Palermo 3
Parma 3
Rosarno 3
San Francisco 3
Silverton 3
Taiyuan 3
Taizhou 3
Tappahannock 3
Toronto 3
Vilnius 3
Wuhan 3
Zhengzhou 3
Altavilla Vicentina 2
Bengaluru 2
Bloomington 2
Totale 5.212
Nome #
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone 179
Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. 149
CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: Results from the Munich Antidepressant Response Signature (MARS) study 145
Age of onset in schizophrenia spectrum disorders: Complex interactions between genetic and environmental factors 140
The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: A 6-month, open-label, randomized controlled pilot trial 122
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: A 6-month, open-label, randomized, pilot trial 121
Cariprazine specificity profile in the treatment of acute schizophrenia: A meta-Analysis and meta-regression of randomized-controlled trials 116
The Role of Genetics in Bipolar Disorder 113
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial 112
22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders 111
Progress and prospects in pharmacogenetics of antidepressant drugs 106
Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response 103
Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study 102
Clinical features and drug induced side effects in early versus late antidepressant responders. 101
Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. 101
A model to investigate SNPs' interaction in GWAS studies 99
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance 96
Neuronal cell adhesion genes and antidepressant response in three independent samples 96
Genome-wide association study of antidepressant response: Involvement of the inorganic cation transmembrane transporter activity pathway 96
null 93
TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. 92
Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients 92
null 92
Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients 91
HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: A meta-analysis 91
Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials 90
Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation 90
Pharmacogenetics in Psychiatry 89
Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance 88
Genetic basis of Bipolar disorder 87
Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR(⁎)D. 87
No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. 87
Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study 87
Epigenetic basis of psychiatric disorders: a narrative review 86
Mechanisms of antidepressant action: an integrated dopaminergic perspective. 85
Pharmacogenetics in major depression: a comprehensive meta-analysis. 85
HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in Schizophrenia 85
Genetics of long-term treatment outcome in bipolar disorder 84
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. 84
Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder 83
Pharmacogenetics of antidepressants. 82
DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy 82
Predictors of switch from depression to mania in bipolar disorder 82
Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics 82
Genetica dei comportamenti impulsivo-aggressivi: possibile applicazione in psichiatria forense? 81
Genetics of serotonin receptors and depression: state of the art. 81
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. 80
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: Common and specific effects of key regulators of fat-mass homoeostasis genes 80
null 79
Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder 79
Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression 79
Shared genetics among major psychiatric disorders. 78
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. 77
Pharmacogenetics of antidepressant response. 76
Pharmacogenetics and depression: A critical perspective 76
Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies 76
null 74
Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials 73
Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications 72
Is Pharmacogenetics Useful in Antidepressant Treatment? 72
null 69
Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder 66
null 64
Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression 64
The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives 63
Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder 62
Refining prediction in treatment-resistant depression: Results of machine learning analyses in the TRD III sample 59
Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice 58
Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study 55
Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns 54
Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples 54
Genetic underpinnings of sociability in the general population 54
Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression 54
A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping 47
Genetics of resilience: Implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression 45
Precision psychiatry in clinical practice 45
Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression 43
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? 41
Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders 38
Genetics of treatment outcomes in major depressive disorder: Present and future 38
Comparison of Mortality Rates between Italian and Foreign-born Patients with Alcohol Use Disorders 38
How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach 37
The search for personalized antidepressant treatments: What have we learned and where are we going 37
Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption 37
Genetic variants associated with psychotic symptoms across psychiatric disorders 36
Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly 34
Genetics and major depressive disorder: Clinical implications for disease risk, prognosis and treatment 34
Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder 33
Clinical, demographic, and genetic risk factors of treatment-attributed suicidality in >10,000 Australian adults taking antidepressants 30
A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response 28
Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts 27
New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR∗D studies: Rare variant analysis and high-density imputation 27
Genetic and Environmental Contribution to Major Depressive Disorder and Self-declared Depression 27
Anxiety disorders and age-related changes in physiology 26
Research domain criteria (Rdoc): A perspective to probe the biological background behind treatment efficacy in depression 26
Genetics of nonpharmacological treatments of depression 25
Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts 24
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder 22
COVID-19 hospitalization rates in individuals with substance or alcohol use disorders 22
An interview with Dr Chiara Fabbri: pharmacogenomics and drug repurposing for treatment-resistant depression 22
Totale 7.282
Categoria #
all - tutte 20.610
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.610


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019183 0 0 0 0 0 0 0 23 22 50 25 63
2019/20202.051 233 42 5 97 207 200 262 288 399 125 106 87
2020/2021978 193 67 34 51 39 10 27 70 119 39 24 305
2021/20221.727 122 85 82 52 154 122 48 256 75 140 311 280
2022/20231.996 170 229 118 176 111 149 123 153 387 63 183 134
2023/2024580 59 124 65 71 52 84 69 56 0 0 0 0
Totale 7.765